Insider Transactions in Q2 2021 at Keros Therapeutics, Inc. (KROS)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+7.15%
|
$0
$0.3 P/Share
|
|
Jun 11
2021
|
Claudia Ordonez Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,000
-82.65%
|
$51,000
$51.22 P/Share
|
|
Jun 11
2021
|
Claudia Ordonez Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$0
$0.48 P/Share
|
|
Jun 11
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,650
-1.11%
|
$135,150
$51.41 P/Share
|
|
Jun 11
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,650
+3.18%
|
$0
$0.3 P/Share
|
|
Jun 07
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
12,796
-0.23%
|
$627,004
$49.14 P/Share
|
|
Jun 04
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
6,619
-0.36%
|
$311,093
$47.69 P/Share
|
|
Jun 03
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
7,895
-0.42%
|
$371,065
$47.92 P/Share
|
|
Jun 02
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
11,529
-0.3%
|
$564,921
$49.9 P/Share
|
|
Jun 01
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
8,812
-0.23%
|
$467,036
$53.25 P/Share
|
|
May 13
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,720
+4.04%
|
$0
$0.21 P/Share
|
|
May 11
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,650
-3.59%
|
$132,500
$50.0 P/Share
|
|
May 11
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,650
+3.46%
|
$0
$0.3 P/Share
|
|
May 11
2021
|
Claudia Ordonez Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$50,000
$50.15 P/Share
|
|
May 11
2021
|
Claudia Ordonez Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$0
$0.48 P/Share
|
|
May 04
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
2,835
-0.15%
|
$153,090
$54.04 P/Share
|
|
May 03
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
44,816
-0.91%
|
$2,554,512
$57.76 P/Share
|
|
Apr 12
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-1.76%
|
$318,000
$60.47 P/Share
|
|
Apr 12
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+6.48%
|
$0
$0.3 P/Share
|
|
Apr 12
2021
|
Claudia Ordonez Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,000
-67.06%
|
$60,000
$60.11 P/Share
|
|
Apr 12
2021
|
Claudia Ordonez Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$0
$0.48 P/Share
|
|
Apr 06
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
9,298
-0.31%
|
$548,582
$59.09 P/Share
|
|
Apr 05
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
27,151
-0.87%
|
$1,601,909
$59.56 P/Share
|
|
Apr 01
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
11,202
-0.27%
|
$660,918
$59.92 P/Share
|
|
Apr 01
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,996
+12.31%
|
$0
$0.11 P/Share
|